Objective: To examine the relation of well-known factors of the metabolic syndrome (MetS) as well as related circulating factors, with risk of colorectal cancer. Methods: We performed a case control study of 306 colorectal cancer cases and 595 matched controls nested in the Northern Sweden Health and Disease Cohort. Levels of C-peptide, glycated haemoglobin (HbA1c), leptin and adiponectin were measured in cryopreserved samples. Body mass index (BMI), systolic and diastolic blood pressure and fasting and post-load plasma glucose, had been measured in a subcohort. Conditional logistic regression was used to calculate odds ratios (OR) of disease, including risk assessments for the MetS factors: obesity (BMI430 kg m À2 ), hypertension (blood pressure X140/90 mmHg or use of anti-hypertensive drugs) and hyperglycaemia (fasting glucose X6.1 mmol l À1 or post-load glucose in capillary plasma X8.9 mmol l À1 ). Results: None of the studied variables were significantly associated with risk across quartiles. Presence of obesity, hypertension and hyperglycaemia significantly increased the risk of colorectal cancer; OR for three vs null factors was 2.57 (95% Confidence Interval [CI] 1.20-5.52; P trend ¼ 0.0021), as compared to a 30 to 70% increased risk for the factors in single. Similarly, top decile levels of C-peptide, HbA1c and leptin/adiponectin ratio were associated with an increased risk; ORs for top vs deciles 1-9 were 1.56 (95% CI 0.93-2.62; P ¼ 0.090), 1.83 (95% CI 1.00-3.36; P ¼ 0.051) and 1.50 (95% CI 0.83-2.71; P ¼ 0.18), respectively. Conclusions: Our study support the view that components of the MetS increase risk of colorectal cancer, and further suggests that only very high levels of metabolic factors confer an increased risk.
Introduction
Colorectal cancer is much more common in the Western world than in developing countries, 1 as are also obesity and type 2 diabetes. 2 In parallel, analytical studies have shown that obesity, assessed by body mass index (BMI), and prevalent diabetes increase risk of colorectal cancer. [3] [4] [5] [6] Obesity is a main cause of insulin resistance and hyperinsulinaemia, which precedes type 2 diabetes. 7 As insulin has been shown to stimulate tumour growth in vitro 8 it has been hypothesized to be a key mediator between obesity and cancer. [9] [10] [11] Most, [12] [13] [14] [15] [16] [17] [18] but not all, 19 prospective studies have shown a weak positive association between circulating insulin levels and colon or colorectal cancer risk. The metabolic syndrome (MetS)Fincluding obesity, insulin resistance, hypertension and dyslipidaemiaFis related to an increased risk of diabetes and cardiovascular disease (CVD). 20, 21 Despite using different definitions of the MetS, most prospective studies that investigated the joint effect of several MetS factors have shown an increased risk of colorectal cancer incidence or mortality in subjects with several factors present. [22] [23] [24] [25] [26] However, in some of these studies the effect of single and combined factors was of similar magnitude, [22] [23] [24] and one study showed no association between the MetS and colorectal cancer risk. 14 The aim of this prospective study was to investigate the association between factors of the MetSFobesity, hypertension and hyperglycaemiaFas well as circulating metabolic factors strongly related to the MetSFC-peptide, glycated haemoglobin (HbA1c), leptin and adiponectinFwith colorectal cancer risk.
Materials and methods
The study cohort The Northern Sweden Health and Disease Cohort consists of three subcohorts; the Västerbotten Intervention Project (VIP), the Northern Sweden WHO Monitoring of Trends of Cardiovascular disease study (MONICA) and the local Mammography Screening Project (MSP). The present study included participants of the VIP and the MSP.
The VIP is an ongoing project since 1985, to which all residents of Västerbotten county are invited to a health survey at the age of 40, 50 and 60 years; between 1985-1996, residents were also invited at the age of 30. About 59% of invited persons take part in the health survey and participants have been shown to have similar socioeconomic status as the background population. 27 Instructions before the health survey are to fast for a minimum of eight hours (four hours before 1992) and to avoid physical activity, smoking and snuffing the last hours prior to the survey. In the present study, 95% of subjects had fasted for four hours or more before the blood draw. The survey includes measurements of height, weight and, after five minutes rest in supine position, blood pressure and a blood draw. Glucose, cholesterol and triglycerides are measured in fresh plasma, although triglycerides have not been measured in all health centres throughout the years. An oral glucose tolerance test with 75 g glucose, is normally only performed in participants with a fasting glucose level below 7.0 mmol l À1 and without known diabetes mellitus. After two hours, post-load glucose level is measured in fresh capillary plasma. The health survey also includes a questionnaire, including questions on social life, life style and medication. The MSP has been ongoing since 1995. All women residing in Västerbotten county and who are 50-70 years old, are invited every 2-3 years for breast cancer screening with mammography. The exact age at enrolment and time between screenings have varied over the years. Participants of the MSP are asked to donate blood for future research. Fasting before the examination is not required but fasting time since last meal is recorded and 95% of subjects in the current study had fasted for less than four hours. Anthropometric measurements in the MSP have only been performed the last couple of years.
For VIP and MSP participants who give consent for use of their specimen in future research, blood samples are fractioned into plasma, buffy coat and erythrocyte aliquots and cryopreserved at À801C. In September 2004, blood had been collected from 77 589 participants in the VIP and from 26 872 participants in the MSP. The present study was approved by the research ethical committee of Umeå University Hospital.
Case and control selection
In September 2004, a linkage of the VIP and the MSP to the regional cancer register, covering approximately 99% of colorectal cancer diagnoses, was performed. Out of 351 cases diagnosed with colorectal cancer after baseline measurement, 16 cases with a previous cancer diagnosis (except nonmelanoma skin cancer, ICD0 44) were excluded. Another 20 subjects were excluded due to a small remaining sample volume and nine subjects had no sample available due to blocking of another study. A total of 306 cases, 220 from the VIP and 86 from the MSP, were included in the present study. ICD0 18.0 and 18.2-18.9 were used for identification of colon cancer and ICD0 19.9 and 20.9 for rectal cancer. Information on tumour site and the Dukes' tumour stage was extracted from medical records and pathology reports. There were 194 colon cancers and 112 rectal cancers; 50 (16%) tumours were Dukes' stage A, 101 (33%) stage B, 117 (38%) stage C, and in 38 (12%) cases, no surgery was performed and consequently no staging information was available.
For each case, two controls with no cancer diagnosis (except non-melanoma skin cancer) at the date of diagnosis of the index case were randomly selected from the same subcohort. Case-control sets were matched for sex, age at enrolment (76 months), date at blood sampling (72 months) and fasting time before blood draw. In a few cases, the matching criteria were broadened to 71 year for baseline age, and to 73 months for date at blood sampling. For 17 cases, only one control fulfilled the matching (or broadened) criteria. ) is also included in the WHO definition, but was omitted in our major analyses as data was missing for 26% of the VIP-subjects.
Classification of factors in the metabolic syndrome

Biochemical analyses
Fasting and post-load glucose levels were measured at each health care centre by the hexokinase method (Boehringer ). Intra-batch coefficients of variation (CV) were 1.9% (at 5.0 ng ml À1 ) for C-peptide, 11.9% (at 9.6 ng ml
À1
) for leptin and 6.2% (at 13.7 mg ml À1 ) for adiponectin. Corresponding inter-batch CVs were 4.4, 10.9 and 12.6%, respectively. HbA1c levels were measured at the Department of Clinical Chemistry, Karolinska University Hospital, Solna, Sweden. Analyses were performed on cryopreserved erythrocyte fraction measured by high performance liquid chromatography (Bio-Rad, Variant II); a method with intra-and inter-batch CVs of less than 5% within low and high HbA1c levels. HbA1c levels are expressed as monoS units (National Glycohemoglobin Standardization Program unit Â 0.9718À0.8925), as is used in clinical chemistry in Sweden. In all biochemical analyses, case-control sets were analysed in the same batch and laboratory personnel were blinded to case-control status. Since both plasma and erythrocytes samples were not available for all subjects, 86 case-control sets were exclusively analysed for plasma C-peptide, leptin and adiponectin and 15 sets were analysed for HbA1c levels in erythrocytes only.
Intraclass correlations were calculated from two measurements of fasting levels of C-peptide and leptin in plasma and HbA1c in erythrocytes in blood samples collected one month apart, from 38 men (mean age ¼ 71 years, range ¼ 66-84 years), not part of the current study group. 
Statistical analyses
Since some of the studied variables were skewed and/or had outliers, we used non-parametric statistical tests. The MannWhitney U-test was used to evaluate differences in continuous parameters between cases and controls. To assess associations between variables, we used Spearman's partial correlation coefficients, adjusted for case-control status, sex, age, smoking status (past/never-smoker or current smoker) and fasting time before blood draw. Odds ratios (OR), and 95% CIs were calculated by conditional logistic regression. Risk for increasing quartile levels, or tertile levels for small subgroups, were calculated for all variables separately, with cut-off points defined according to the distribution among controls. We calculated cut-off points for C-peptide separately for subjects with less or more than four hours fasting time as C-peptide levels were significantly higher among non-fasting subjects. Since women had significantly higher plasma levels of leptin and adiponectin than men, separate sex-specific cut-offs were used for these variables. In subjects from the VIP, we also calculated ORs for categories of BMI, blood pressure and plasma glucose and for presence vs no presence of MetS factors. In VIP subjects, ORs for top vs deciles 1-9 of C-peptide, HbA1c, leptin, adiponectin and the leptin/adiponectin ratio were also assessed. Linear trends in ORs were assessed by likelihood ratio tests, assigning an increasing score of 1, 2, 3 etc. to each increasing quartile or categorical level, respectively. Formal tests of heterogeneity between the ORs in subgroups were performed using w 2 statistics. All statistical tests and corresponding P-values were two-sided. The Statistical Analysis System software (SAS Institute, Cary, NC) 29 was used in all statistical analyses.
Results
Baseline characteristics of study subjects are presented in Table 1 . Cross-sectional interrelationships between variables showed that BMI was strongly correlated with leptin levels (r ¼ 0.69) and the leptin/adiponectin ratio (r ¼ 0.64), and moderately with C-peptide levels (r ¼ 0.52) ( Table 2 ). The correlation between plasma C-peptide and insulin levels in a subset of 370 subjects with data on insulin from a previous study 16 was 0.82.
In conditional regression analyses of quartile levels, none of the studied factors were significantly associated with risk (Table 3 ). High levels of diastolic blood pressure was borderline-significantly positively associated with risk; OR for top vs bottom quartile was 1.59 (95% CI 0.94-2.70; P trend ¼ 0.070) after adjustment for BMI, and the association was stronger and significant among men and in the subgroup of Dukes' stage C. ORs for top vs bottom quartiles were 2.30 (95% CI 1.08-4.87; P trend ¼ 0.065) and 3.30 (95% CI 1.30-8.37; P trend ¼ 0.016), respectively, but the risk estimates did not differ significantly from the corresponding groups of women and Dukes' stage A-B (P heterogeneity 40.05).
Since non-fasting subjects were from the mammography cohort, analyses stratified for fasting time before blood sampling included women only, and were due to a small subsample performed across tertiles. Increasing C-peptide levels were weakly positively associated with risk among fasting women (n cases ¼ 93), but inversely associated with risk among non-fasting women (n cases ¼ 84). Unadjusted ORs for top vs bottom tertile were 1.23 (95% CI 0.64-2.34; P trend ¼ 0.53) and 0.82 (95% CI 0.42-1.58; P trend ¼ 0.54), respectively, but the difference in risks was not significant. No significant association with risk of any of the measured variables was found in analyses of subgroups of tumour localisation, age at blood sampling or time between recruitment and diagnosis. The prevalence of current smokers was
The metabolic syndrome and colorectal cancer risk T Stocks et al The metabolic syndrome and colorectal cancer risk T Stocks et al In the VIP, eight subjects had data missing for BMI. In the MSP, data on BMI is only available since 1998 and was therefore not adjusted for in the full study cohort. (Table 4) . Furthermore, increasing levels of fasting glucose was related to an increased risk; OR for diabetic (X7.0 mmol l
À1
) vs normal (o6.1 mmol l À1 ) levels was 2.03 (95% CI 0.86-4.79; P trend ¼ 0.016), after adjustment for BMI. This association was stronger and remained significant in the subgroups of: women (OR: 7.86, 95% CI 1.31-47.2; P trend ¼ 0.0027), colon cancers (OR: 2.84, 95% CI 1.01-8.05; P trend ¼ 0.0081), among subjects older than the median age of 59.6 years (OR: 2.73, 95% CI; 1.04-7.16, P trend ¼ 0.010) and among cases with a time to diagnosis longer than the median of 6.1 years (OR: 4.74, 95% CI; 1.18-19.0; P trend ¼ 0.0044). These subgroup analyses were based on small samples and the difference in risk across categories of fasting glucose was only significant between women and men (P heterogeneity ¼ 0.0021), whereas differences in risk estimates between colon vs rectum, older vs younger subjects and between subgroups of lagtime did not differ significantly. Subgroup analyses across categories of BMI, blood pressure and post-load glucose did not show any material differences between subgroups. The groups according to Dukes' staging were too small for risk assessment in categories.
The MetS factors obesity, hypertension and hyperglycaemia were positively associated with colorectal cancer risk, with ORs of 1.77 (95% CI 1.11-2.82; P ¼ 0.016), 1.30 (95% CI 0.90-1.86; P ¼ 0.16) and 1.70 (95% CI 1.09-2.63; P ¼ 0.018), respectively ( Figure 1) . The presence of an increasing number of these factors was associated with a significant increase in risk, with an OR for three vs null factors of 2.57 (95% CI 1.20-5.52; P trend ¼ 0.0021). Similarly to fasting glucose, but less apparent, risk with three MetS factors was higher among women (OR: 4.16, 95% CI 1.30-13.3; P trend ¼ 0.022) than among men (OR: 1.57, 95% CI 0.53-4.70; P trend ¼ 0.038), and also somewhat stronger in the subgroups of colon cancer, older subjects and among subjects with a longer lagtime (data not shown). None of the differences between the respective subgroups were significant. In 153 case-control sets with data on triglycerides, hypertriglyceridaemia was not associated with colorectal cancer risk; OR, adjusted for BMI, was 0.97 (95% CI 0.62-1.51; P ¼ 0.89).
Approximately 10% of controls were obese and/or had elevated levels of fasting or post-load glucose. To compare risk estimates for these factors with risks for high levels of Cpeptide, HbA1c, leptin, adiponectin and the leptin/adiponectin ratio, we assessed risk for the top tenth level (cut-offs based on controls' levels) vs deciles 1-9 of these factors among subjects from the VIP. All factors were positively associated with risk: ORs, adjusted for BMI, was for C-peptide 1.56 (95% CI 0.93-2.62; P ¼ 0.090); HbA1c 1.83 (95% CI 1.00-3.36; P ¼ 0.051); leptin 1.38 (95% CI 0.76-2.48; P ¼ 0.29); adiponectin 1.89 (95% CI 1.10-3.27; P ¼ 0.022) and for the leptin/ adiponectin ratio 1.50 (95% CI 0.83-2.71; P ¼ 0.18). The metabolic syndrome and colorectal cancer risk T Stocks et al
Discussion
In this prospective study, factors of the MetS were positively associated with colorectal cancer risk, and simultaneous presence of obesity, hypertension and hyperglycaemia significantly increased the risk more than two-fold. Notably, these components were associated with risk only at very high levels and correspondingly top decile levels of C-peptide, HbA1c, leptin and adiponectin were also associated with risk. The studied factors showed no significant association with risk across quartiles. Presently, there is no universally accepted definition of the MetS. 32 Studies on the association with colorectal cancer risk used different MetS factors and cut-off points, which somewhat complicates comparisons between studies. Nevertheless, four out of five previous prospective studies (excluding a very small study of 54 cases 26 ), consistently reported a 1.4-1.5-fold significant increased risk of incident or fatal colorectal cancer in subjects with three or more MetS factors present (Table 5) . [22] [23] [24] [25] The fifth study showed no such association. 14 In that study, however, hyperglycaemiaFa strong risk factor in our and other studiesFwas not included as a factor of the MetS. The 2.5-fold increased risk with several MetS factors found in our study is stronger than what was reported in previous studies. One explanation for this stronger association may be that we applied the WHO definition of the MetS, which generally has higher cut-off points than those used by others. Additionally, some previous studies included serum triglycerides and/or cholesterol in their modelsFfactors that in our and other studies were not associated with risk. 
MetS factor
Presence OR (95%CI)
2 4
Odds ratio Cases/controls Figure 1 Odds ratios for colorectal cancer for presence of the MetS factor obesity, hypertension and hyperglycaemia, respectively, and for an increasing number present. Odds ratios for hypertension and hyperglycaemia are adjusted for BMI. Three subjects who reportes having diabetes, with data missing for post-load glucose (no OGTT in the VIP if known diabetes mellitus), but with top quartile levels of HbA1c, and who reported diet and exercise as the only treatment of diabetes (a treatment of type 2 diabetes only), were classified as hyperglycaemic, despite normal fasting glucose levels. P trend refers to the P-value for a test (two sided) of linear trend, calculated by numerical scores, increasing with each Mets factor present.
The metabolic syndrome and colorectal cancer risk T Stocks et al All studies were cohort studies, except reference 14, which was a nested case-control study. Relative risk is used as expression for relative risks, hazards ratios or odds ratios. Risks presented are from the most adjusted models presented in each study. If not otherwise stated, relative risks refer to presence vs absence of the MetS factor.
The WHO cut-off limits for BMI, blood pressure and glucose have been designed to predict morbidity and mortality from diabetes and CVD. 28, 30, 31 In our study, these cut-off points were well above the top quartile limit for all variables but diastolic blood pressure. Interestingly, diastolic blood pressure was the only variable that showed an increased risk across quartiles. High blood pressure has in most, 22, 23, 26, 33 but not all, 24, 34 previous studies been related to a moderate, but mostly non-significant, increased risk of colorectal cancer incidence or mortality. Based on our observations, we suggest that the WHO cut-off points of risk factors, originally set for prediction of CVD, may also be suitable for estimates of colorectal cancer risk. Impaired fasting glucose or diabetic fasting glucose levels were associated with a two-fold increased risk in our study. The association was stronger and significant in the subgroups of women, colon cancers, elderly subjects and in cases with a long time between recruitment and diagnosis, whereas subgroup analyses of categories for BMI, blood pressure and post-load glucose, showed no significant associations with risk. HbA1c reflects average glucose concentration during the past two months 35 and has been shown to remain stable in stored blood samples. 36 In our quality control, HbA1c showed an intraclass correlation of 0.98 between measurements drawn one month apart. Similarly to fasting glucose, top decile levels of HbA1c were positively related to risk in the full study group and more strongly so among women and for colon cancer (data not shown). Although these subgroup analyses were based on small samples, the consistency in the association between high glucose concentration and risk suggests that glucose is an important factor in colo(rectal) cancer development. In support of our findings, previous studies on the MetS consistently showed that hyperglycaemia, together with overweight, was the strongest single risk factor of MetS factors ( Table 5 ). The weaker association observed for postload glucose in our study, may partly be biased by that a higher proportion of VIP cases than controls with elevated fasting glucose levels had data missing for post-load glucose. Obesity and diabetes have been consistently associated with an increased colorectal cancer risk. [3] [4] [5] [6] A possible underlying mediator is insulin resistance and high insulin levels; insulin stimulates tumour growth in vitro 8 and hyperinsulinaemia induces elevated levels of free IGF-I, a strong mitogen. 9,10,37 C-peptide reflects insulin secretion well, 38 but neither C-peptide levels in this study nor insulin levels in our previous study, 16 showed a significant association with risk. Similarly, out of seven prospective studies on insulin/C-peptide levels, [12] [13] [14] [15] [17] [18] [19] only three showed a significant positive association with risk. 14, 15, 17 The weak associations observed may be influenced by a large within subject-variation of insulin/C-peptide levels. 39 An imprecise estimate of long-term exposure with one single measurement induces regression dilution bias and thus attenuates an association. However, in our study we did not find an association between any other factor related to insulin and insulin resistanceFHbA1c, leptin and adiponectinFwith risk in analyses across quartiles, and compared to C-peptide levels, these factors are more stable over time and are not affected by fasting status. 35, 40, 41 46, 47 Nevertheless, top decile levels of these factors and of C-peptide were in our study positively associated with risk, suggesting that only very high concentrations of these factors increases risk. Adiponectin is inversely related to insulin resistance and was in our study negatively correlated with all measured factors. The increased risk at very high adiponectin levels was therefore not expected. However, both leptin and adiponectin are produced by adipose tissue and it has been suggested that leptin relative to adiponectin concentrations is a better marker of insulin resistance than these factors in single. 48, 49 This was supported in our study by that the leptin/adiponectin ratio was more strongly related to Cpeptide and glucose markers than was each of the factors. Strengths of our study include the use of a well-defined population-based cohort, linkage to a cancer registry with a virtually complete coverage of cancer diagnoses and the use of a wide range of components related to the MetS. Our study was limited by that MetS factors were not measured in the MSP cohort. Furthermore, smoking is a possible confounder, 50 but we only had a rough estimate on smoking status, without data on smoking intensity or duration.
In conclusion, we found that obesity, hypertension and hyperglycaemia were associated with an increased risk of colorectal cancer, and the simultaneous presence of these MetS factors was associated with a more than two-fold increase in risk. Accordingly, top tenth levels of C-peptide, HbA1c and the leptin/adiponectin ratio were also associated with an increased risk, whereas no significant association was observed for the studied factors across quartiles. Our study thus support that components of the MetS increase the risk of colorectal cancer, but suggests that only very high levels of metabolic factors confer an increased risk. The combined presence of several risk factors may constitute a somewhat higher risk than factors in single.
